Pharmaceutical company Pharma 5 has developed Morocco’s first cannabis-based medicine and first locally produced active pharmaceutical ingredient derived from the plant, marking a new step in the country’s medical cannabis industry.
The medicine is designed to treat severe forms of epilepsy that do not respond to conventional treatments. Its active ingredient, cannabidiol (CBD), has been purified to more than 98% and meets European Pharmacopoeia standards.
The project follows five years of research and development and an investment of more than 200 million MAD. Pharma 5 says it controls the entire production chain, from regulated cannabis cultivation in the Rif to CBD extraction, purification and medicine manufacturing.
The initiative also supports 70 families in the region through 20 hectares of cannabis cultivation. More than 10 tonnes of plant material have been processed to pharmaceutical standards.
The project falls under Law 13-21, which regulates the legal uses of cannabis, and involved cooperation with the National Agency for the Regulation of Cannabis Activities and the Moroccan Agency for Medicines and Health Products.
Pharma 5 said the initiative aims to strengthen local pharmaceutical production and develop Morocco’s medical cannabis sector.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.